Literature DB >> 12088924

The value of plasma markers for the clinical behaviour of phaeochromocytomas.

E van der Harst1, W W de Herder, R R de Krijger, H A Bruining, H J Bonjer, S W J Lamberts, A H van den Meiracker, T H Stijnen, F Boomsma.   

Abstract

OBJECTIVE: Phaeochromocytomas (PCCs) are widely known for their clinical unpredictability. This study intends to define predictive plasma markers for their variable postoperative behaviour. Furthermore, the diagnostic accuracy of these plasma tests was determined. DESIGN AND METHODS: A retrospective correlative study was performed in a series of 83 operated and four autopsied patients in order to correlate preoperative catecholamine (CAT) levels of 103 PCCs with their clinical behaviour. In a subset of cases, chromogranin-A (Chr-A) and enzymes/precursors of the CAT biosynthesis were studied for their predictive value.
RESULTS: Basal CAT levels were elevated in 81/87 instances (sensitivity: 93%). Four of six cases with normal measurements showed only medullary hyperplasia. Larger PCCs, particularly those showing necrosis, capsular and vascular invasion, secreted higher CAT levels. Bilateral, hereditary tumours were less productive than their unilateral counterparts. Extra-adrenal PCCs secreted significantly lower levels of epinephrine (EPI) than intra-adrenal tumours. Fourteen patients developed metastases. According to Kaplan-Meier estimations, patients with higher levels of dopamine, norepinephrine (NE) and aromatic l-amino acid decarboxylase as well as lower ratios of EPI/EPI+NE, had significantly shorter metastases-free intervals. Existence of preoperative hypertension, left ventricular hypertrophy and measured blood pressures showed significant positive relationships with CAT levels, but not with Chr-A.
CONCLUSIONS: These data showed that plasma CAT measurement is a sensitive method in the diagnostic work-up of PCCs. Those tumours producing normal levels are commonly small and asymptomatic. Furthermore, certain secretion patterns are indicative of the presence of metastases as well as the size and site of sporadic and syndrome-related PCCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088924     DOI: 10.1530/eje.0.1470085

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  29 in total

1.  Dopamine-Secreting Paraganglioma in the Retroperitoneum.

Authors:  Yusuke Matsuda; Noriko Kimura; Takanobu Yoshimoto; Yoshihiro Sekiguchi; Junzo Tomoishi; Ichiro Kasahara; Yoshihito Hara; Yoshihiro Ogawa
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 2.  Pheochromocytomas and paragangliomas: assessment of malignant potential.

Authors:  Tim I M Korevaar; Ashley B Grossman
Journal:  Endocrine       Date:  2011-10-25       Impact factor: 3.633

3.  Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.

Authors:  Graeme Eisenhofer; Jacques W M Lenders; Gabriele Siegert; Stefan R Bornstein; Peter Friberg; Dragana Milosevic; Massimo Mannelli; W Marston Linehan; Karen Adams; Henri J Timmers; Karel Pacak
Journal:  Eur J Cancer       Date:  2011-10-28       Impact factor: 9.162

Review 4.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

5.  Pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Karel Pacak
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 6.  PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Authors:  Garima Gupta; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

Review 7.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

8.  Gene expression profiling of benign and malignant pheochromocytoma.

Authors:  Frederieke M Brouwers; Abdel G Elkahloun; Peter J Munson; Graeme Eisenhofer; Jennifer Barb; W Marston Linehan; Jacques W M Lenders; Ronald De Krijger; Massimo Mannelli; Robert Udelsman; Idris T Ocal; Barry L Shulkin; Stefan R Bornstein; Jan Breza; Lucia Ksinantova; Karel Pacak
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

Review 9.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 10.  Adrenal tumors: how to establish malignancy ?

Authors:  M Fassnacht; W Kenn; B Allolio
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.